Cartesian Therapeutics, Inc. (RNAC) stock
RNACNasdaqPharmaceutical PreparationsFiscal year ends December 31
$6.08−0.27 (-4.25%)
Close on Nov 16, 2026Market cap $183.95MP/E –Yield –
Cartesian Therapeutics r&d expenses
Research and development expenses are spending on new products and technology.
Cartesian Therapeutics's R&D Expenses for the twelve months ending Jun 30, 2026 was $68.39M, up 30.9% year over year. For fiscal 2025 it was $58.03M, up 28.7% from the year before. Over ten years it grew 9.7% a year on average. The highest annual figure on record is $72.38M in fiscal 2022.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $58.03M | +28.7% |
| FY2024 | Dec 31, 2024 | $45.11M | -36.7% |
| FY2023 | Dec 31, 2023 | $71.26M | -1.5% |
| FY2022 | Dec 31, 2022 | $72.38M | +5.3% |
| FY2021 | Dec 31, 2021 | $68.74M | +26.1% |
| FY2020 | Dec 31, 2020 | $54.51M | +27.5% |
| FY2019 | Dec 31, 2019 | $42.74M | -10.4% |
| FY2018 | Dec 31, 2018 | $47.69M | +5.6% |
| FY2017 | Dec 31, 2017 | $45.17M | +52.1% |
| FY2016 | Dec 31, 2016 | $29.70M | +29.3% |
| FY2015 | Dec 31, 2015 | $22.98M | +119.1% |
| FY2014 | Dec 31, 2014 | $10.49M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $20.43M | +37.4% |
| Q1 FY2026 | Mar 31, 2026 | $19.46M | +32.6% |
| Q4 FY2025 | Dec 31, 2025 | $14.69M | +29.9% |
| Q3 FY2025 | Sep 30, 2025 | $13.80M | +21.1% |
| Q2 FY2025 | Jun 30, 2025 | $14.87M | +17.4% |
| Q1 FY2025 | Mar 31, 2025 | $14.67M | +50.7% |
| Q4 FY2024 | Dec 31, 2024 | $11.31M | -48.3% |
| Q3 FY2024 | Sep 30, 2024 | $11.40M | -12.3% |
| Q2 FY2024 | Jun 30, 2024 | $12.66M | -28.8% |
| Q1 FY2024 | Mar 31, 2024 | $9.74M | -47.7% |
| Q4 FY2023 | Dec 31, 2023 | $21.85M | +15.2% |
| Q3 FY2023 | Sep 30, 2023 | $13.00M | -21.4% |
| Q2 FY2023 | Jun 30, 2023 | $17.78M | -7.3% |
| Q1 FY2023 | Mar 31, 2023 | $18.62M | +5.3% |
| Q4 FY2022 | Dec 31, 2022 | $18.97M | -6.6% |
| Q3 FY2022 | Sep 30, 2022 | $16.54M | -21.1% |
| Q2 FY2022 | Jun 30, 2022 | $19.18M | +32.6% |
| Q1 FY2022 | Mar 31, 2022 | $17.69M | +36.0% |
| Q4 FY2021 | Dec 31, 2021 | $20.32M | +34.6% |
| Q3 FY2021 | Sep 30, 2021 | $20.95M | +50.1% |
| Q2 FY2021 | Jun 30, 2021 | $14.46M | +34.8% |
| Q1 FY2021 | Mar 31, 2021 | $13.00M | -11.7% |
| Q4 FY2020 | Dec 31, 2020 | $15.09M | -0.4% |
| Q3 FY2020 | Sep 30, 2020 | $13.96M | +72.3% |
| Q2 FY2020 | Jun 30, 2020 | $10.73M | -11.6% |
| Q1 FY2020 | Mar 31, 2020 | $14.72M | +100.2% |
| Q4 FY2019 | Dec 31, 2019 | $15.15M | +47.7% |
| Q3 FY2019 | Sep 30, 2019 | $8.10M | -31.8% |
| Q2 FY2019 | Jun 30, 2019 | $12.13M | -15.8% |
| Q1 FY2019 | Mar 31, 2019 | $7.35M | -34.0% |
| Q4 FY2018 | Dec 31, 2018 | $10.26M | -24.7% |
| Q3 FY2018 | Sep 30, 2018 | $11.89M | +25.1% |
| Q2 FY2018 | Jun 30, 2018 | $14.41M | +31.0% |
| Q1 FY2018 | Mar 31, 2018 | $11.14M | +0.9% |
| Q4 FY2017 | Dec 31, 2017 | $13.62M | +23.5% |
| Q3 FY2017 | Sep 30, 2017 | $9.50M | +57.8% |
| Q2 FY2017 | Jun 30, 2017 | $10.99M | – |
| Q1 FY2017 | Mar 31, 2017 | $11.04M | – |
| Q4 FY2016 | Dec 31, 2016 | $11.03M | – |
| Q3 FY2016 | Sep 30, 2016 | $6.02M | – |
See a number that looks wrong?